Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Blood Cancer Journal"
DOI: 10.1038/s41408-020-0297-2
Abstract: Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma Maria… read more here.
Keywords: krd following; carfilzomib lenalidomide; lenalidomide dexamethasone; following asct ... See more keywords